Department of Paediatric Immunology, Haemato-Oncology, Bone Marrow Transplantation and Auto-immune diseases, Leiden University Medical Centre, Leiden, The Netherlands.
Bone Marrow Transplant. 2010 Jan;45(1):79-85. doi: 10.1038/bmt.2009.92. Epub 2009 May 4.
The aim of our study was to assess the cumulative incidence and severity ('burden') of late effects in a single-centre cohort of childhood haematopoietic stem cell transplantation (HSCT) survivors, at least 2 years after transplantation. The presence and severity of late effects in each survivor was documented according to the Common Terminology Criteria for Adverse Events (version 3.0). The burden of late effects was graded from mild to disabling/life-threatening. Risk factors for a high burden of late effects were assessed by univariate and multivariate logistic regression analyses. Among 162 survivors of HSCT seen in our late effects outpatient clinic, cumulative incidence of late effects was 93.2% after a median follow-up time of 7.2 years (range 2.0-21.0 years) after HSCT. The burden of late effects was mild, moderate, severe and disabling in 28, 41, 24 and 1% of survivors respectively. Risk factors for a severe or disabling burden of late effects were older age at HSCT (P for trend <0.001) and a conditioning regimen including irradiation OR 2.2, 95% CI 1.1-4.7, P=0.03). In conclusion, a high burden of late effects is found in childhood HSCT survivors after a median follow-up of only 7 years.
我们的研究目的是评估单中心儿童造血干细胞移植(HSCT)幸存者在移植后至少 2 年时的晚期效应的累积发生率和严重程度(“负担”)。根据不良事件通用术语标准(版本 3.0),记录每位幸存者晚期效应的存在和严重程度。晚期效应的负担分为轻度至残疾/危及生命。通过单变量和多变量逻辑回归分析评估晚期效应高负担的风险因素。在我们的晚期效应门诊诊所中观察到的 162 名 HSCT 幸存者中,在 HSCT 后中位随访时间为 7.2 年(范围为 2.0-21.0 年)后,晚期效应的累积发生率为 93.2%。晚期效应负担分别为轻度、中度、重度和残疾的幸存者比例分别为 28%、41%、24%和 1%。HSCT 年龄较大(趋势 P<0.001)和包括照射的调理方案是发生严重或致残性晚期效应负担的危险因素 OR 2.2,95%CI 1.1-4.7,P=0.03)。总之,在中位随访仅 7 年后,儿童 HSCT 幸存者中发现晚期效应负担较高。